If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Lyumjev Summary of Product Characteristics (SmPC)
Lyumjev® ▼ (insulin lispro): Citrate and Effect as Excipient
Citrate is an excipient in Lyumjev formulation that acts to increase vascular permeability.
- Citrate in Formulation
citrate is an excipient that acts to increase vascular permeability,
resulting in the accelerated absorption of insulin lispro.1-4
is a common GRAS ingredient used in many pharmaceutical
Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro
formulation containing citrate and treprostinil demonstrates faster
absorption and onset of insulin action in healthy subjects
[abstract]. Diabetes. 2017;66(suppl 1):A253. American Diabetes
Association abstract 976‑P.
Michael MD, Zhang C, Siesky AM, et al. Exploration of the Mechanism
of Accelerated Absorption for a Novel Insulin Lispro Formulation
[abstract]. Diabetes. 2017;66(suppl 1):A250.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Lyumjev [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:August 06, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org